US-based healthcare education company Forefront Collaborative in partnership with MadMicrobe Studios and Vectorform has unveiled a metastatic non-small cell lung cancer (mNSCLC) immersive learning feature with its ImmerseRX augmented reality (AR) app.

Using the app, healthcare professionals can pinch and zoom to scale, lift, and rotate 3D models to better understand tumour immune evasion pathways, immunotherapy, and pathological diagnosis. The app will also suggest testing required before an optimal treatment decision for patients suffering from mNSCLC.

The collaboration is said to use Forefront Collaborative’s medically accurate content, 3D visualisation from MadMicrobe Studios, Vectorform’s augmented reality (AR) app development along with input from expert faculties.

Forefront Collaborative senior vice president and general manager Ro Brual said: “The ImmerseRX mNSCLC experience represents a tangible advance in scientific learning.

“We see AR in gaming, but this is a first for the metastatic non-small cell lung cancer CME space. That’s good news for patients.”

Forefront Collaborative is an ACCME-accredited company that has been developing continuing medical education (CME) experience for over 25 years. The firm partners with various experts in multiple therapeutic areas to develop CME.

MadMicrobe Studios is a team of medical artists and animators who develop medical animation, device animation, virtual reality (VR), and AR for the healthcare, pharmaceutical, and broadcast industries.

Vectorform, which is an NTT DATA company, is a digital transformation and innovation company that makes digital products and experiences for brands that focus on life, movement, and energy ecosystems.

The ImmerseRX mNSCLC app can be downloaded from the App Store and Google Play.